Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,940 shares of the life sciences company’s stock after selling 2,289 shares during the quarter. Yousif Capital Management LLC’s holdings in Illumina were worth $6,673,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Versant Capital Management Inc lifted its stake in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC increased its holdings in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares in the last quarter. Spire Wealth Management raised its position in shares of Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock worth $63,000 after acquiring an additional 97 shares during the period. Private Trust Co. NA boosted its stake in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in shares of Illumina during the 3rd quarter valued at about $63,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 1.5 %

ILMN opened at $122.80 on Friday. The business’s 50 day moving average price is $137.80 and its 200 day moving average price is $135.42. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market capitalization of $19.48 billion, a PE ratio of -12.33 and a beta of 1.10. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. As a group, equities research analysts expect that Illumina, Inc. will post 4.13 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Piper Sandler reduced their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. UBS Group upped their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. TD Cowen increased their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $164.84.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.